Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 8Biliary Tract Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Mesothelioma, Malignant 5Melanoma 5Liver Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Diabetes Mellitus, Insulin-Dependent, 12 4Neoplasm Metastasis 3Lung Neoplasms 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Mesothelioma 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Adenocarcinoma Of Esophagus 2Vascular Neoplasms 1Uveal Melanoma 1

Interventions

Gemcitabine 13Doxorubicin 8Docetaxel 7Trabectedin 5pazopanib 4Nivolumab 4Temozolomide 3Specimen Handling 3Sorafenib 3rucaparib 2pembrolizumab 2liposomal doxorubicin 2durvalumab 2brostallicin 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Letrozole 2Ifosfamide 2Dacarbazine 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1talimogene laherparepvec 1sotigalimab 1soblidotin 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leiomyosarcoma × tremelimumab × Clear all
NCT02815995 2025-06-12

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

M.D. Anderson Cancer Center

Phase 2 Completed
57 enrolled 18 charts
Sarcoma

Hemangiosarcoma, Leiomyosarcoma, Osteosarcoma, Sarcoma, Synovial, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡